All In Biotech

Drug Trial Radar · NCT06726148

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Apr 3, 2025

Primary completion

Sep 25, 2028

Study completion Sep 25, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

Conditions

  • Advanced HR+/HER2- Breast Cancer
  • Advanced CCNE1-amplified Solid Tumors
  • Extensive-stage Small Cell Lung Cancer

Interventions

  • ECI830Drug

    Experimental

  • ribociclibDrug

    Approved medication

  • fulvestrantDrug

    Approved medication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Incidence of dose-limiting toxicities (DLTs)Time frame: 2 years
  2. Phase I: Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: 2 years
  3. Phase I: Number of participants with dose interruptions, reductions and discontinuationsTime frame: 2 years
  4. Phase II: PFS rate at 6 months per local response evaluation criteria in solid tumors (RECIST) v1.1Time frame: 6 months

Locations

33 sites in 16 countries. Site status is shown where the registry gives one.

  • University of California LA

    Los Angeles, California · Recruiting

  • Florida Cancer Specialists

    Fort Myers, Florida · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • WA Uni School Of Med

    St Louis, Missouri · Recruiting

  • Memorial Sloan Kettering

    New York, New York · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center Uni of Te

    Houston, Texas · Recruiting

  • Fred Hutch Cancer Research

    Seattle, Washington · Recruiting

  • Novartis Investigative Site

    Clayton, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    Melbourne, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    Toronto, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Nanjing, Jiangsu, China · Recruiting

  • Novartis Investigative Site

    Xian, Shanxi, China · Recruiting

  • Novartis Investigative Site

    Brno, Czechia · Recruiting

  • Novartis Investigative Site

    Copenhagen, Denmark · Recruiting

  • Novartis Investigative Site

    Odense C, Denmark · Recruiting

  • Novartis Investigative Site

    Bordeaux, France · Recruiting

  • Novartis Investigative Site

    Saint-Herblain, France · Recruiting

  • Novartis Investigative Site

    Heidelberg, Germany · Recruiting

  • Novartis Investigative Site

    Ulm, Germany · Recruiting

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, Germany · Recruiting

  • Novartis Investigative Site

    Haifa, Israel · Recruiting

  • Novartis Investigative Site

    Tel Aviv, Israel · Recruiting

  • Novartis Investigative Site

    Milan, MI, Italy · Recruiting

  • Novartis Investigative Site

    Modena, MO, Italy · Recruiting

  • Novartis Investigative Site

    Chuo Ku, Tokyo, Japan · Recruiting

  • Novartis Investigative Site

    Singapore, Singapore · Recruiting

  • Novartis Investigative Site

    Seoul, Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Tainan, Taiwan · Recruiting

  • Novartis Investigative Site

    London, Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.